Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive’s Stephen Gunnion that the company will move forward with plans to list on the New York Stock Exchange as it hits milestones in the development of its programs and investor interest grows.
Commissioning says Todos is also in the final stages of launching a crowdfunding campaign for its 3CL Pharma subsidiary and its Long COVID trials of Tollovir and Tollovid. This will free up funds for its Videssa breast cancer blood test, which it plans to commercialize in 2023.
Freeing up cash flow will also be a major step towards its uplisting, he adds.
“We’re really focused on creating a virtuous circle where we’re generating revenue, reinvesting that revenue to generate more revenue, and all of that allows us to launch new products,” he says. “We see this kind of 3CL Pharma funding allowing Todos to really get back to its pre-pandemic business of driving sales.”
#ProactiveInvestors #TodosMedical #3CLPharma #Crowdfunding #NYSE #OTCQB #Tollovid #Tollovir #Videssa
